Click image to enlarge
S-PLEX is MSD’s ultra-sensitive assay platform. It can dramatically improve the sensitivity of immunoassays, reducing the lower limit of detection (LLOD) by 10- to 1000-fold over other assay methods. The S-PLEX Human Eotaxin-3 Assay has the essential components for an ultra-sensitive assay that measures Eotaxin-3 in a single-analyte format. For detailed instructions on running the Eotaxin-3 assay, please see the product insert in the "Documentation" tab below.
Related Key Terms: CCL26, MIP-4α, SCYA26, TSC-1, IMAC, CC chemokine, eosinophils, eosinophilia, inflammation, allergy, asthma, eosinophilic esophagitis, Churg Strauss syndrome
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Application(s)
|
|
Cytokines & Chemokines
,
Immunology/Inflammation
|
|
|
Analyte(s)
|
|
Eotaxin-3
|
|
|
Species
|
|
Human
|
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
MESO SECTOR S 600MM
|
|
|
Plate Type
|
|
96-well
|
|
|
Capture Antibody
|
|
Mouse monoclonal
|
|
|
Detection Antibody
|
|
Mouse monoclonal
|
|
|
LLOD (Sensitivity)
|
|
59 fg/mL
|
|
|
Dynamic Range
|
|
59 - 266,000 fg/mL
|
|
|
Sample Type
|
|
Serum, Plasma, Cell Culture Supernatant, CSF
|
|
|
Recombinant standards
|
|
Expressed in E. coli
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Gene ID(s)
|
|
10344
|
|
|
UniProt ID(s)
|
|
Q9Y258
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Diluent 57
|
≤-10 °C
|
1 bottle
(10 mL)
|
|
|
|
S-PLEX Human Eotaxin-3 Antibody Set
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
Human Eotaxin-3 Calibrator
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
S-PLEX Coating Reagent C1
|
≤-70 °C
|
1 vial
(300 μL)
|
|
|
|
S-PLEX Detect D2
|
≤-70 °C
|
1 each
(50 μL)
|
|
|
|
S-PLEX Detect D1
|
≤-70 °C
|
1 each
(1.7 mL)
|
|
|
|
S-PLEX 96-Well SECTOR Plate
|
2-8 °C
|
1 each
(1 plate)
|
|
|
|
|
2-8 °C
|
1 bottle
(50 mL)
|
|
|
|
|
2-8 °C
|
1 bottle
(8 mL)
|
|
|
|
|
RT
|
1 bottle
(18 mL)
|
|
|
|
S-PLEX Enhance E1
|
≤-10 °C
|
1 each
(1.7 mL)
|
|
|
|
S-PLEX Enhance E2
|
≤-10 °C
|
1 vial
(1.7 mL)
|
|
|
|
S-PLEX Enhance E3
|
≤-70 °C
|
1 each
(50 μL)
|
|
|
|
|
≤-10 °C
|
1 vial
(500 μL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Diluent 57
|
≤-10 °C
|
1 bottle
(50 mL)
|
|
|
|
S-PLEX Human Eotaxin-3 Antibody Set
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
Human Eotaxin-3 Calibrator
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
S-PLEX Coating Reagent C1
|
≤-70 °C
|
1 vial
(300 μL)
|
|
|
|
S-PLEX Detect D2
|
≤-70 °C
|
5 each
(50 μL)
|
|
|
|
S-PLEX Detect D1
|
≤-70 °C
|
5 each
(1.7 mL)
|
|
|
|
S-PLEX 96-Well SECTOR Plate
|
2-8 °C
|
5 each
(1 plate)
|
|
|
|
|
2-8 °C
|
1 bottle
(50 mL)
|
|
|
|
|
2-8 °C
|
1 bottle
(40 mL)
|
|
|
|
|
RT
|
1 bottle
(90 mL)
|
|
|
|
S-PLEX Enhance E1
|
≤-10 °C
|
5 each
(1.7 mL)
|
|
|
|
S-PLEX Enhance E2
|
≤-10 °C
|
5 vial
(1.7 mL)
|
|
|
|
S-PLEX Enhance E3
|
≤-70 °C
|
5 each
(50 μL)
|
|
|
|
|
≤-10 °C
|
1 vial
(500 μL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Diluent 57
|
≤-10 °C
|
5 bottle
(50 mL)
|
|
|
|
S-PLEX Human Eotaxin-3 Antibody Set
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
Human Eotaxin-3 Calibrator
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
S-PLEX Coating Reagent C1
|
≤-70 °C
|
5 vial
(300 μL)
|
|
|
|
S-PLEX Detect D2
|
≤-70 °C
|
25 each
(50 μL)
|
|
|
|
S-PLEX Detect D1
|
≤-70 °C
|
25 each
(1.7 mL)
|
|
|
|
S-PLEX 96-Well SECTOR Plate
|
2-8 °C
|
25 each
(1 plate)
|
|
|
|
|
2-8 °C
|
5 bottle
(50 mL)
|
|
|
|
|
2-8 °C
|
5 bottle
(40 mL)
|
|
|
|
|
RT
|
5 bottle
(90 mL)
|
|
|
|
S-PLEX Enhance E1
|
≤-10 °C
|
25 each
(1.7 mL)
|
|
|
|
S-PLEX Enhance E2
|
≤-10 °C
|
25 vial
(1.7 mL)
|
|
|
|
S-PLEX Enhance E3
|
≤-70 °C
|
25 each
(50 μL)
|
|
|
|
|
≤-10 °C
|
5 vial
(500 μL)
|
|
|
|
Product Inserts
|
|
|
|
Certificate of analysis
|
|
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
|
|
|
|
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial
|
|
|
|
CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease
|
|
|
|
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.
|
|
|
|
Biomarkers of inflammation and coagulation are associated with mortality and Hepatitis flares in persons coinfected with HIV and Hepatitis viruses.
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters